This article appeared as part of the Daily Sensemaker newsletter – one story a day to make sense of the world. To receive it in your inbox, featuring content exclusive to the newsletter, sign up for free here.
Weight-loss drug maker Novo Nordisk has teamed up with OpenAI to discover new drugs and get them to patients faster. This makes it the latest pharma firm to partner with Sam Altman’s company, which has also struck agreements with Sanofi, Eli Lilly and Moderna. It is another bet OpenAI is making to carve out a path towards profitability: the company has floated the idea of taking royalties from pharma firms that make new discoveries using its tools. For Novo Nordisk, which makes Wegovy and Ozempic, the agreement with OpenAI is a chance at revival. It was Europe’s most valuable company in 2024. But it has fallen behind its competitors and its share price has fallen by nearly half in the past year.
Newsletters
Choose the newsletters you want to receive
View more
For information about how The Observer protects your data, read our Privacy Policy